Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer

Area of Science:

• Oncology
• Immunotherapy
• Head and Neck Cancer Research

Background:

• Patients with HPV-unrelated head and neck squamous cell carcinoma (HNSCC) exhibit limited efficacy with PD-1 inhibitors alone.
• Transforming growth factor β (TGF-β) signaling can suppress anti-tumor T cell responses, potentially hindering PD-1 inhibitor effectiveness.

Purpose of the Study:

• To evaluate the safety and efficacy of concurrent PD-L1 and TGF-β inhibition in patients with HPV-unrelated HNSCC.
• To assess the impact of this combination therapy on pathologic response in primary tumors.

Main Methods:

• A clinical trial involving 14 patients with HPV-unrelated HNSCC.
• Treatment with bintrafusp alfa, a bifunctional fusion protein targeting both PD-L1 and TGF-β.
• Pathologic evaluation of primary tumors to assess response.

Main Results:

• Five out of 14 patients achieved at least a partial pathologic response in their primary tumors.
• No complete pathologic responses were observed in primary tumors or metastatic lymph nodes.
• The combination therapy demonstrated a manageable safety profile.

Conclusions:

• Concurrent neoadjuvant inhibition of PD-L1 and TGF-β represents a rational therapeutic strategy for HPV-unrelated HNSCC.
• This approach may enhance pathologic response rates and improve clinical outcomes in this patient population.
• Further investigation is warranted to optimize this combination therapy.